April 25, 1953: Crick and Watson crack the code of life as paper reveals ...
In 1986, the first gene for an inherited condition - the gene defective in chronic granulomatous disease - was identified using only gene mapping strategies. Now, scientists can manufacture important proteins, like insulin and growth hormone, for ...
BT.com - Fri, 24 Apr 2015 16:26

Ending social stigma against leprosy patients (Social Feature)
Leprosy, also known as Hansen's disease, is a chronic infection caused by bacteria. Initially, infections are without symptoms and typically remain this way for five to as long as 20 years. Symptoms that develop include granulomas of the nerves ...
New Kerala - Sat, 25 Apr 2015 01:37



Novel Antibiotic Formulation For Treating Acinetobacter Infections in CF ...
... pneumonia (HABP), 2) treatment of pulmonary infections by Burkholderia cepacia complex in patients with chronic granulomatous disease, a genetic disorder characterized by chronic severe infections and dysfunction in certain cells of the immune ...
Cystic Fibrosis News Today - Wed, 22 Apr 2015 05:01

Pernix Therapeutics Closes Acquisition of Zohydro ER Franchise
Zohydro ER has warnings for: interactions with CNS depressants; elderly, cachectic, debilitated patients, and those with chronic pulmonary disease; hypotensive effects; patients with head injury or increased intracranial pressure; and concomitant use ...
Yahoo Finance UK - Fri, 24 Apr 2015 09:52



FDA clears new formulation of The Medicine Co's Minocin (MDCO)
Pulmonary infections including pneumonia or lung abscess in patients with chronic granulomatous disease caused by B. cepacia complex. Among the benefits of QIDP status is a five-year period of market exclusivity for the indication, if approved.
Seeking Alpha - Mon, 20 Apr 2015 05:33

FDA Approves New Formulation of MINOCINĀ® (minocycline) for Injection
Business Wire (press release) - Mon, 20 Apr 2015 04:01

Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R ...
ACTIMMUNE is currently approved by the U.S. Food and Drug Administration (FDA) for use in two rare diseases. It is indicated to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD), a genetic ...
MarketWatch - Fri, 10 Apr 2015 04:03



Horizon Pharmas Actimmune Gets Fast Track Status
Fast track designation is granted to candidates that are being developed for the treatment of a serious or life-threatening disease or condition and is believed to possess the capability to address unmet medical needs. On receiving this designation ...
Zacks.com - Mon, 13 Apr 2015 09:52

Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog
Nasdaq - Mon, 13 Apr 2015 09:52

US fast-track for Horizon's Actimmune
PharmaTimes - Mon, 13 Apr 2015 01:46

Horizon gets FDA fast track status for actimmune to treat Friedreich's ataxia
Pharmaceutical Business Review - Mon, 13 Apr 2015 04:00

Half-matched bone marrow transplant offers cure for debilitating non-cancer ...
It would take four months of tests and procedures before doctors diagnosed Nico with chronic granulomatous disease . It's a rare, inherited genetic disorder where the immune system can't fight off some types of bacteria and fungi. CGD sufferers often ...
ABC2 News - Tue, 07 Apr 2015 16:37


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014